Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 14Rectal Neoplasms 10Pancreatic Neoplasms 7Colonic Neoplasms 6Biliary Tract Neoplasms 5Adenocarcinoma 4HER2-positive Gastric Cancer 3Esophageal Neoplasms 3Cholangiocarcinoma 3Ovarian Neoplasms 2Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Locally Advanced Gastric Cancer 2Cirrhosis, Familial, with Pulmonary Hypertension 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Low Rectal Adenocarcinoma 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Small Intestine Cancer × Oxaliplatin × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡